Kancera AB
Solna, SE· latest recorded location
KANCERA AB is named on 15 US grants and 15 published applications in this corpus. Its most frequent classification is C07D (Heterocyclic compounds).
- Granted patents
- 15
- Published applications
- 15
- Inventors
- 22
- Granted in 2026 so far
- 0
- Most recent grant
- 1 Apr 2025
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2013 | 0 | 2 |
| 2014 | 0 | 1 |
| 2015 | 1 | 1 |
| 2016 | 2 | 1 |
| 2017 | 1 | 0 |
| 2018 | 1 | 1 |
| 2019 | 1 | 1 |
| 2020 | 2 | 1 |
| 2021 | 1 | 4 |
| 2022 | 1 | 0 |
| 2023 | 3 | 2 |
| 2024 | 1 | 0 |
| 2025 | 1 | 1 |
By publication year.
Technology areas
Share of 30 documents
- C07DHeterocyclic compounds20
- A61KMedicines and medical preparations15
- A61PTherapeutic uses of medicines15
- C07CAcyclic or carbocyclic compounds6
- C07FAcyclic, carbocyclic or heterocyclic compounds containing elements other than carbon, hydrogen, halogen4
- C07KPeptides4
- C12NMicroorganisms or enzymes2
- C12YEnzymes1
Recent patents
- Process for the stereoselective preparation of chiral 2-[(hetero) arylalkylsulfanyl]pyrimidines and products obtainable therefrom1 Apr 2025US 12,264,165 B2
- Phosphate and phosphonate derivatives of 7-amino-5-thio-thiazolo[4,5-d]pyrimidines and their use in treating conditions associated with elevated levels of CX3CR1 and/or CX3CL113 Aug 2024US 12,060,380 B2
- Process for the stereoselective preparation of chiral 2-[(hetero)arylalkylsulfanyl]pyrimidines and products obtainable therefrom4 Jul 2023US 11,691,988 B2
- 2-phenylimidazo[4,5-b]pyridin-7-amine derivates useful as inhibitors of mammalian tyrosine kinase ROR1 activity30 May 2023US 11,660,303 B2
- Process for the steroselective preparation of chiral 2- [(hetero)arylalkylsulfanyl] pyrimidines and products obtainable therefrom3 Jan 2023US 11,542,281 B2
- Process for the Steroselective Preparation of Chiral 2-[(Hetero)Arylalkylsulfanyl]Pyrimidines and Products Obtainable Therefrom17 Jul 2025US 2025/0230170 A1
- Process for the Steroselective Preparation of Chiral 2-[(Hetero)Arylalkylsulfanyl]Pyrimidines and Products Obtainable Therefrom12 Oct 2023US 2023/0322807 A1
- A Process for the Steroselective Preparation of Chiral 2-[(Hetero)Arylalkylsulfanyl]Pyrimidines and Products Obtainable Therefrom2 Mar 2023US 2023/0068240 A1
- Phosphate and phosphonate derivatives of 7-amino-5-thio-thiazolo[4,5-d]pyrimidines and their use in treating conditions associated with elevated levels of cx3cr1 and/or cx3cl14 Nov 2021US 2021/0340167 A1
- Phosphate and phosphonate derivatives of 7-amino-5-thio-thiazolo[4,5-d]pyrimidines and their use in treating conditions associated with elevated levels of cx3cr1 and/or cx3cl123 Sep 2021US 2021/0292349 A1
Most cited
By later US patents
- Biological inhibitors of ROR1 capable of inducing cell death29US 9,150,647 B22015
- Antibodies against ROR1 and uses thereof24US 9,266,952 B22016
- Bicyclic hydroxamic acids useful as inhibitors of mammalian histone deacetylase activity2US 10,654,814 B22020
- 2-phenyl-3H-imidazo[4,5-B]pyridine derivates useful as inhibitors of mammalian tyrosine kinase ROR1 activity1US 10,550,113 B22020
- Phosphate and phosphonate derivatives of 7-amino-5-thio-thiazolo[4,5-d]pyrimidines and their use in treating conditions associated with elevated levels of CX3CR1 and/or CX3CL11US 11,339,183 B22022